Shareholders support management proposals at SYGNIS Pharma´s AGM with overwhelming majority

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Annual & Special Corporate Meetings

Heidelberg (euro adhoc) - Shareholders support management proposals at SYGNIS
Pharma´s AGM with overwhelming majority

Heidelberg, 25 November 2011 -  At  today´s  Annual  General  Meeting  (AGM)  of
SYGNIS  Pharma  AG  (Frankfurt:  LIOK;  ISIN   DE000A1E9B74;   Prime   Standard)
shareholders  representing  about  73  percent  of  the  capital  approved   all
proposals of the Management with an overwhelming majority. Main  decisions  were
related to the discharge of the members of the Supervisory  and  the  Management
Board for the past Fiscal Year, the election of the members of  the  Supervisory
Board as well as the creation of contingent capital for convertible bonds.

All members of the Supervisory Board have been re-elected,  with  the  exception
of Mr. Friedrich Christ. Mr.  Christ  has  meanwhile  retired  and  it  was  his
personal decision not to stand for re-election.  From  today´s  AGM  onwards, 
Dr.  Wolf-Dieter Starp,  Head  of  Global  M&A  at  BASF  SE,  has  been 
elected  to  the Supervisory Board.

Prof. Dr. Friedrich von Bohlen und Halbach, chairman of  the  Supervisory  Board
thanked Mr. Christ for his work and efforts during the  last  years  for  SYGNIS
Pharma AG. He welcomed Dr. Starp as a new member of the Supervisory Board.

At the AGM the two members of the Management  Board,  Peter  Willinger  and  Dr.
Frank Rathgeb, confirmed that the data on SYGNIS´ current AXIS 2 efficacy  study
for AX200 for the treatment of acute stroke  is  expected  to  be  published  in
December 2011.

About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg,  is  a  specialty  pharmaceutical
company listed on the Prime Standard of the German stock exchange.  The  Company
is focused on the research, development and marketing  of  innovative  therapies
for the treatment of disorders of the  Central  Nervous  System.  These  include
Stroke, Amyotrophic Lateral Sclerosis and neurological disorders resulting  from
injuries to the brain or spinal cord. All these disorders are  characterized  by
the fact that, as the disease progresses,  nerve  cells  are  damaged  and  die.
Although there  is  great  medical  demand,  there  are  currently  no  or  only
inadequate treatment options available.

For further information please contact:

|Dr. Franz-Werner Haas                  |
|Senior Vice President Operations       |
|+49 (0) 6221 454 812                   |
|         |

  Julia Phillips
  FTI Consulting
  Tel.: +44 (0) 20 7269 7187

Some statements included in this  press  release,  relating  neither  to  proven
financial results nor other  historical  data,  should  be  viewed  as  forward-
looking, i.e. not definite. Such statements are  mainly  predictions  of  future
results, trends, plans or goals. These statements should not  be  considered  to
be total guarantees since given their very nature they are subject to known  and
unknown risks and imponderability and can be affected  by  other  factors  as  a
consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG
may deviate greatly from the  established  conclusions  or  implied  predictions
contained in such statements. SYGNIS does not undertake to  publicly  update  or
revise these statements in the light of new information  or  future  results  or
for any other reason.

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

company:     SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: